Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00322686 · ClinicalTrials.gov registry record · Phase 2
Study of Oglemilast for the Treatment of Asthma
A Phase 2 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00322686: Completed Phase 2 study, sponsored by Forest Laboratories.
NCT00322686 is a Phase 2 study that has completed, run by Forest Laboratories. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00322686, a Phase 2 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether oglemilast is safe and effective in the treatment of allergen-induced asthma.
Interventions
- DRUG Oglemilast
- DRUG Placebo then Oglemilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2006-05 |
| Phase | Phase 2 |
What the finished NCT00322686 record still lists
NCT00322686 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Oglemilast is the first listed.
NCT00322686 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00322686 about?
NCT00322686 is a clinical study titled "Study of Oglemilast for the Treatment of Asthma". The purpose of this study is to determine whether oglemilast is safe and effective in the treatment of allergen-induced asthma.
What is the current status of trial NCT00322686?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2006-05.
What interventions are being tested in trial NCT00322686?
The interventions under investigation include: Oglemilast (DRUG), Placebo then Oglemilast (DRUG).
Who is sponsoring clinical trial NCT00322686?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00322686's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia